Arcturus Therapeutics Quarterly Balance Sheets Chart
Quarterly
|
Annual
Arcturus Therapeutics Quarterly Balance Sheets Table
Quarterly
|
Annual
| Unit: USD | 2019-03-31 | 2018-12-31 |
|---|---|---|
| assets | ||
| current assets: | ||
| cash and cash equivalents | 31,220,000 | 36,709,000 |
| accounts receivable | 4,457,000 | 4,481,000 |
| prepaid expenses and other current assets | 929,000 | 638,000 |
| total current assets | 36,606,000 | 41,828,000 |
| property and equipment | 2,016,000 | 1,975,000 |
| operating lease right-of-use asset | 5,690,000 | |
| equity-method investment | ||
| non-current restricted cash | 107,000 | 107,000 |
| total assets | 44,419,000 | 44,198,000 |
| liabilities and shareholders' equity | ||
| current liabilities: | ||
| accounts payable | 4,118,000 | 2,398,000 |
| accrued liabilities | 2,766,000 | 3,907,000 |
| deferred revenue | 7,728,000 | 6,272,000 |
| total current liabilities | 14,612,000 | 12,577,000 |
| deferred revenue, net of current portion | 8,025,000 | 7,534,000 |
| long-term debt | 9,945,000 | 9,911,000 |
| operating lease liability, net of current portion | 5,483,000 | |
| deferred rent | 534,000 | |
| total liabilities | 38,065,000 | 30,556,000 |
| shareholders' equity | ||
| ordinary shares: nis 0.07 par value; 30,000 shares authorized, 10,762 issued, 10,719 outstanding and 43 held in treasury at march 31, 2019; nis 0.07 par value; 30,000 shares authorized, 10,762 issued, 10,719 outstanding and 43 held in treasury at december 31, 2018 | 214,000 | |
| additional paid-in capital | 58,701,000 | 58,302,000 |
| accumulated deficit | -52,561,000 | -44,874,000 |
| total shareholders' equity | 6,354,000 | |
| total liabilities and shareholders' equity | 44,419,000 | |
| restricted cash | ||
| short-term investments | ||
| intangible asset held for sale | ||
| equity method investment | 288,000 | |
| liabilities and shareholders’ equity | ||
| commitments and contingencies | ||
| shareholders’ equity: | ||
| ordinary shares: 30,000 shares authorized, 10,762 issued, 10,719 outstanding and 43 held in treasury at december 31, 2018; nis 0.07 par value; 30,000 shares authorized, 10,699 issued, 10,656 outstanding and 43 held in treasury at december 31, 2017; | 214,000 | |
| accumulated other comprehensive loss | ||
| total shareholders’ equity | 13,642,000 | |
| total liabilities and shareholders’ equity | 44,198,000 |
We provide you with 20 years of balance sheets for Arcturus Therapeutics stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as asset and liabilities, payables and receivables, long debts and short debts, cash and inventories, expenses and profits. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Arcturus Therapeutics. Explore the full financial landscape of Arcturus Therapeutics stock with our expertly curated balance sheets.
The information provided in this report about Arcturus Therapeutics stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.